Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2012
11/22/2012CA2835798A1 Epha4 is a disease modifier in motor neuron disease
11/22/2012CA2835735A1 Pharmaceutical compositions comprising neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
11/22/2012CA2835717A1 Method for treatment of solid malignancies including advanced or metastatic solid malignancies
11/22/2012CA2835642A1 Regulation of nitric oxide release and biofilm development
11/22/2012CA2835496A1 Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
11/22/2012CA2835336A1 Pharmaceutical combination for use in the treatment of diabetes type 2 patients
11/22/2012CA2835265A1 Lixisenatide as add-on therapy to basal insulin in type 2 diabetes
11/22/2012CA2835259A1 Lixisenatide and metformin for treatment of diabetes type 2
11/22/2012CA2835229A1 Quinazoline derivatives for the treatment of viral infections and further diseases
11/22/2012CA2835169A1 Substituted indole derivatives for the treatment of immunological disorders
11/22/2012CA2834813A1 Skin and hair regeneration using polysaccharide-based hydrogels
11/22/2012CA2834710A1 Compositions and methods for the treatment of skin diseases
11/22/2012CA2834699A1 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
11/22/2012CA2834574A1 Deuterated derivatives of ivacaftor
11/22/2012CA2834566A1 Therapeutic anti-igf1r combinations
11/22/2012CA2834077A1 Inhibitors of bruton's tyrosine kinase
11/22/2012CA2833219A1 Medical food for cognitive decline
11/22/2012CA2832384A1 1,3-oxazines as bace1 and/or bace2 inhibitors
11/22/2012CA2832334A1 New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
11/22/2012CA2831403A1 Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
11/22/2012CA2826725A1 High concentration olopatadine ophthalmic composition
11/22/2012CA2820845A1 A water soluble composition comprising curcumin having enhanced bioavailability and process thereof
11/21/2012EP2524922A1 Optically active compound of prulifloxacin for treating infection and preparation method thereof
11/21/2012EP2524921A1 Novel Crystalline Salts of Asenapine
11/21/2012EP2524920A1 Novel Crystalline Asenapine Hydrochloride Salt Forms
11/21/2012EP2524919A1 Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
11/21/2012EP2524918A1 Imidazopyrazines derivates as kinase inhibitors
11/21/2012EP2524917A1 Fused pyridine derivatives
11/21/2012EP2524915A1 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
11/21/2012EP2524912A1 Amine derivatives
11/21/2012EP2524694A1 Use of sigma ligands in diabetes type-2 associated pain
11/21/2012EP2524693A1 Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
11/21/2012EP2524692A1 Anti-inflammatory analgesic adhesive patch for external use
11/21/2012EP2524691A1 An antioxidant composition
11/21/2012EP2524689A1 Oral preparation having improved quality
11/21/2012EP2524688A1 Composition for modified release comprising ranolazine
11/21/2012EP2524686A1 Pigmentation-preventing or -ameliorating agent
11/21/2012EP2524229A1 Method for preparing polybiotinylated compounds
11/21/2012EP2524058A1 Mutations in the lnk gene in patients with myeloproliferative neoplasms and other hematolymphoid malignancies
11/21/2012EP2524039A2 Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
11/21/2012EP2524038A1 Modulation of transforming growth factor-beta 1 expression
11/21/2012EP2523966A1 Certain chemical entities, compositions, and methods
11/21/2012EP2523963A1 2,5-substituted oxazolopyrimidine derivatives
11/21/2012EP2523962A1 Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
11/21/2012EP2523961A1 2,5,7-substituted oxazolopyrimidine derivatives
11/21/2012EP2523960A1 Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
11/21/2012EP2523959A1 Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring
11/21/2012EP2523958A1 Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring
11/21/2012EP2523957A1 Tricyclic heterocyclic compounds, compositions and methods of use thereof
11/21/2012EP2523956A1 Anti - infective pyrido (1,2 -a) pyrimidines
11/21/2012EP2523955A1 Novel substituted bicyclic triazole derivatives as gamma secretase modulators
11/21/2012EP2523954A1 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES
11/21/2012EP2523953A1 Preparation of 4-amino-thiazoles and 3-amino-1,2,4-thiadiazoles and their use as allosteric modulators of metabotropic glutamate receptors
11/21/2012EP2523952A1 Thiazole and oxazole kinase inhibitors
11/21/2012EP2523951A1 Inhibitors of flaviviridae viruses
11/21/2012EP2523950A1 Inhibitors of flaviviridae viruses
11/21/2012EP2523949A1 Novel substituted triazole derivatives as gamma secretase modulators
11/21/2012EP2523948A1 Pro-drugs of (e) -7- (3- (2-amino-1-fluoroethylidene) piperidin-1-yl) -1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
11/21/2012EP2523947A1 Process for the preparation of strontium ranelate
11/21/2012EP2523946A1 Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
11/21/2012EP2523945A1 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
11/21/2012EP2523938A1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7
11/21/2012EP2523936A1 Compounds which modulate the cb2 receptor
11/21/2012EP2523731A1 Use of an adrenal hormone-modifying agent
11/21/2012EP2523691A1 Halogenated ether complex
11/21/2012EP2523670A1 Method for producing reservoir layer for hoof treatment and reservoir layer
11/21/2012EP2523669A1 Combination, kit and method of reducing intraocular pressure
11/21/2012EP2523668A1 Treatment of multiple sclerosis
11/21/2012EP2523667A2 Lyophilized cake formulations
11/21/2012EP2523666A1 A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
11/21/2012EP2523665A1 Voltage-gated sodium channel blockers
11/21/2012EP2523664A1 Compounds and methods
11/21/2012EP2523663A1 Pharmaceutical use of multicyclic compounds as anti-aids agents
11/21/2012EP2523662A1 "compositions comprising amino acids for prevention and/or treatment of renal disorders"
11/21/2012EP2523661A1 Compounds for the treatment of autism
11/21/2012EP2523660A2 Solid-forming local anesthetic formulations for pain control
11/21/2012EP2523657A1 Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
11/21/2012EP2523654A2 Immediate release compositions of acid labile drugs
11/21/2012EP2523564A2 A nutritional supplement to improve supplementary target protein fraction (tpf) delivery, intracellular absorption and utilization
11/21/2012EP2523563A1 Method of treating neurological conditions with cardiac glycosides
11/21/2012EP2523562A1 Nicotinic acetylcholine receptor modulators
11/21/2012EP2523561A1 DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b]PURIN-4(5H)-ONE AND METHODS OF USE THEREOF
11/21/2012EP2523560A1 Compounds and methods
11/21/2012EP2523558A1 Oxadiazole beta carboline derivatives as antidiabetic compounds
11/21/2012EP2523557A1 Methods of providing weight loss therapy in patients with major depression
11/21/2012EP2523553A1 Methods and compositions for treating bleeding disorders
11/21/2012EP2523552A1 Pyrazolo[1,5-a]pyrimidines as mark inhibitors
11/21/2012EP2260833B1 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic
11/21/2012CN202542107U Lansoprazole and hydrotalcite composition
11/21/2012CN202537982U Compound loratadine ibuprofen pseudoephedrine sulfate controlled release tablet
11/21/2012CN202537981U Nitroglycerin patch
11/21/2012CN202537979U Cataplasm
11/21/2012CN202537977U Taxol injection
11/21/2012CN202537976U Hydroxycamptothecin injection
11/21/2012CN1980930B 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and the use in the form of a DPP-IV inhibitor
11/21/2012CN1950110B Cyclodextrin inclusion complexes of pyrimidine-2,4,6-triones
11/21/2012CN1930127B Process for the synthesis of cxcr4 antagonist
11/21/2012CN1763018B Oxazolidinone analog compound
11/21/2012CN102791862A Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)
11/21/2012CN102791861A Treatment of Filaggrin (FLG) related diseases by modulation of FLG expression and activity
1 ... 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 ... 7860